You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Mallinckrodt
Medtronic
Colorcon

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,474,752

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,474,752
Title:Method for treating a pulmonary hypertension condition
Abstract: A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.
Inventor(s): Gerber; Michael J. (Denver, CO), Dufton; Christopher (Nederland, CO)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:14/182,208
Patent Claims: 1. A method for treating a pulmonary hypertension condition in a human patient, comprising administering to the patient a therapeutically effective amount of ambrisentan and a therapeutically effective amount of an agent selected from the group consisting of sildenafil, tadalafil and vardenafil.

2. The method of claim 1, wherein the pulmonary hypertension condition is pulmonary arterial hypertension (PAH).

3. The method of claim 2, wherein the PAH is of WHO Class II, III or IV.

4. The method of claim 1, wherein the agent is tadalafil.

5. The method of claim 1, wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg.

6. The method of claim 1, wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg.

7. The method of claim 1, wherein the ambrisentan and the agent are administered in one dosage form for administration at the same time.

8. The method of claim 1, wherein the ambrisentan and the agent are administered separately at different times.

9. A method for treating pulmonary arterial hypertension (PAH) in a human patient, comprising administering to the patient a therapeutically effective amount of ambrisentan and a therapeutically effective amount of tadalafil.

10. The method of claim 9, wherein the PAH is idiopathic PAH.

11. The method of claim 9, wherein the PAH is of WHO Class II, III or IV.

12. The method of claim 9, wherein the ambrisentan is administered in a daily dosage amount of about 1 mg to about 25 mg.

13. The method of claim 9, wherein the ambrisentan is administered in a daily dosage amount of about 2.5 mg to about 10 mg.

14. The method of claim 13, wherein the ambrisentan and the tadalafil are administered in one dosage form for administration at the same time.

15. The method of claim 13, wherein the ambrisentan and the tadalafil are administered separately at different times.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Baxter
Merck
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.